Alimentiv is a contract research organization specializing in clinical trials for gastrointestinal diseases, particularly inflammatory bowel conditions such as ulcerative colitis and Crohn's disease. The company conducts and manages clinical studies, offering services in trial design, patient recruitment, data collection, and regulatory compliance to support pharmaceutical development.
Headquartered in London, Ontario, Canada, Alimentiv operates across North America and internationally, partnering with major drug manufacturers including Takeda on projects like the VERDICT trial. It focuses on treat-to-target strategies and disease clearance metrics in its research efforts.
Formerly operating as Robarts Clinical Trials, Alimentiv has built a reputation for expertise in gastroenterology research. As an independent entity, it positions itself as a leader in providing specialized CRO services within the competitive clinical research industry, emphasizing innovative methodologies to advance therapeutic options for digestive disorders.
Also known as Robarts Clinical Trials.
None yet. When a new project in the record names Alimentiv as owner, partner or investor, it shows here.
Treating to corticosteroid-free disease clearance with vedolizumab lengthened time to first ulcerative colitis complication and cut complication risk by about 70%.
